Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Leases (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Current Leases for 13 consecutive years, with $617000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases rose 2.32% to $617000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $617000.0 through Dec 2025, up 2.32% year-over-year, with the annual reading at $561000.0 for FY2025, 2.0% up from the prior year.
  • Current Leases hit $617000.0 in Q4 2025 for Vistagen Therapeutics, up from $597000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $640000.0 in Q2 2025 to a low of $300.0 in Q4 2021.
  • Historically, Current Leases has averaged $411378.9 across 5 years, with a median of $517100.0 in 2023.
  • Biggest YoY gain for Current Leases was 156700.0% in 2022; the steepest drop was 99.63% in 2022.
  • Year by year, Current Leases stood at $300.0 in 2021, then skyrocketed by 156700.0% to $470400.0 in 2022, then increased by 13.41% to $533500.0 in 2023, then grew by 13.03% to $603000.0 in 2024, then increased by 2.32% to $617000.0 in 2025.
  • Business Quant data shows Current Leases for VTGN at $617000.0 in Q4 2025, $597000.0 in Q3 2025, and $640000.0 in Q2 2025.